The association of exaggerated hypertensive response to exercise and beta-blockers use in hypertensives.

Mert K. U., ŞENER E., Yilmaz A. S., Mert G. Ö., Yetmis F., Dural M., ...Daha Fazla

Clinical and experimental hypertension (New York, N.Y. : 1993), cilt.42, sa.8, ss.707-713, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 42 Sayı: 8
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/10641963.2020.1779284
  • Dergi Adı: Clinical and experimental hypertension (New York, N.Y. : 1993)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.707-713
  • Anahtar Kelimeler: Hypertension, beta blocker, anti-hypertensive, exaggerated blood pressure, hypertensive response to exercise, BLOOD-PRESSURE RESPONSE, ENDOTHELIAL DYSFUNCTION, CARDIOVASCULAR EVENTS, SCIENTIFIC STATEMENT, ARTERIAL STIFFNESS, RISK, MORTALITY, SENSITIVITY, TOLERANCE
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Purpose An elevation in blood pressure (BP) during exercise is the normal physiological response, however an abnormally exaggerated rise in BP, in terms of hypertensive response to exercise (HRE), is seen as a prognostic factor for end-organ damage and mortality. HRE is more common in hypertensive (HT) patients and data are lacking on the effect of antihypertensive medication on HRE. In this study, we evaluated patients who underwent treadmill exercise testing (TET) to reveal the effect of antihypertensive medication on HRE. Materials and Methods A cohort of 2970 individuals underwent TET and data were evaluated for HRE development. HRE has been defined as a systolic BP>210 mmHg in males and >190 mmHg in females throughout the TET. To reveal the effects of antihypertensive medication on HRE, 992 HT patients were analyzed. Results HRE was observed in 11.4% (n= 113) of HT patients and 5.9% (n= 107) of non-HT individuals(p< .001). HRE was observed significantly more in males (57.6% vs. 67.3%;p= .033), and in patients with higher body mass index BMI (29.1 +/- 4.5 vs. 30.3 +/- 5.2;0.033). There was no significant association between medication and HRE development apart from beta-blockers. Also, gender (odds ratio:1.787; 95%CI:1.160-2.751;p= .008), BMI (odds ratio:1.070;95%CI:1.025-1.116;p= .002) and being under beta-blocker treatment (odds ratio:0.637;95%CI:0.428-0.949;p= .026) were found to be independent predictors of HRE in multivariate logistic regression analysis. Conclusion HRE was associated with gender, BMI and beta-blocker use in hypertensive with male gender and higher BMI associated with higher HRE, while beta-blocker-based treatment, either mono- or combination therapy, associated with lower HRE.